SCHOTT Vials DC Demonstrate Resistance against Delamination in New Screening Study
A new series of studies has demonstrated the effectiveness of SCHOTT Vials Delamination Controlled (DC), which can replace existing packaging solutions without re-registration and offers higher product security.
A new series of studies has once again demonstrated the effectiveness of SCHOTT Vials Delamination Controlled (DC). These pharmaceutical vials have a particularly high chemical durability and are therefore less susceptible to delamination. SCHOTT has had this property confirmed in various storage studies. First, substances were used that have already caused product recalls due to delamination. In a second series of studies, the question of how effectively buffer systems can be stored in the new bottle was examined more closely. The result: if the respective substances were stored in SCHOTT Vials DC, the vials remained stable and no glass delamination was observed.
Thanks to SCHOTT Vials DC, pharmaceutical companies now have an interesting alternative course of action against the “phenomenon of delamination”. SCHOTT Vials DC are based on established hot forming principles without any additional post process steps and can therefore replace the packaging that is already being used with approved drugs without causing expensive re-registration. The vials are available in the ISO sizes 2R to 10R. SCHOTT has also already produced larger sizes to meet individual customer needs.
Company name: SCHOTT AG, Germany
Website: http://www.schott.com/
E-mail: chtistina.rettig@schott.com
Name of product: SCHOTT Vials DC
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
